Misdosing Incident Prompts Astellas To Change Muscle Relaxant Succin Name
This article was originally published in PharmAsia News
Executive Summary
A death caused by drug misdosing in Japan has prompted Astellas to change the name for muscle relaxant Succin (suxamethonium) injection. Last November, a patient died after a hospital in Tokushima Prefecture mistakenly administrated Succin to the patient, who was originally prescribed antibacterial Saxizon (hydrocortisone sodium succinate) by Kowa Pharmaceutical. The incident prompted Japan's Ministry of Health, Labor and Welfare to put out a notice to Astellas and nationwide medical facilities. Astellas will now market the drug with its generic name. (Click here for more - Japanese language
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.